Well covered — Manhattan office, single-market bet. A quarterly payer: $0.6175 a share against second-quarter FFO of $1.43 a share, a 43% payout — covered more than twice over on the FFO measure that matters for a REIT, since the quarter's GAAP result was a $0.38-a-share net loss driven by items outside recurring operations. Management raised 2026 FFO guidance to $5.60–$5.90 a share from $4.40–$4.70, Manhattan same-store occupancy rose to 94.7%, replacement leases signed in the quarter at rents 18% above prior fully escalated rents, and same-store cash NOI rose 4.3%. The dividend is well covered; the concentration is the story — this is Manhattan office, and the coverage depends on that one market staying leased.
Key risk: Manhattan office concentration — a single-market, single-sector portfolio means a New York office downturn, a major tenant exit, or a stalled leasing pipeline hits the whole FFO base at once, and asset sales are part of how the balance sheet is currently managed.
Changes if: The FFO payout pushes well past ~43%, Manhattan occupancy falls below 94.7%, or replacement-lease rents turn from +18% mark-to-market to negative. The cushion is the verdict.
- ✓FFO coverage check: 43% of Q2 FFO paid out — $0.6175 against $1.43 a share — and 2026 FFO guidance was raised to $5.60–$5.90, which would put the $2.47 annual dividend at roughly 42–44% of guided FFO.
- ✓Yield check: ~4.9% is earned, not stretched — backed by 94.7% occupancy, 18% positive mark-to-market on replacement leases, and 4.3% same-store cash NOI growth.
- !Concentration check: The entire thesis is Manhattan office: one market, one sector, with a GAAP net loss in the quarter and a share price down about 52% over ten years. Coverage is strong today; the diversification is nil.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.